Catheter Precision Seeks 733% Stock Authorization Hike

TL;DR

**VTAK's massive authorized share increase is a red flag for dilution, signaling potential capital raises that could crush current shareholder value.**

AI Summary

Catheter Precision, Inc. (VTAK) is holding a Special Meeting on October 10, 2025, to address three key proposals. The most significant is a Certificate Amendment Proposal to increase the number of authorized common stock shares from 60 million to 500 million, a substantial 733% increase. This move could facilitate future capital raises or strategic transactions, potentially diluting existing shareholder value. The company also seeks to ratify the appointment of WithumSmith+Brown, PC as its independent registered public accounting firm for the fiscal year ended December 31, 2026. Additionally, stockholders will vote on an Adjournment Proposal, if necessary, to secure votes for the primary proposals. As of the September 10, 2025 record date, there were 1,487,266 shares of Common Stock outstanding, held by 74 record holders. The Board of Directors unanimously recommends a 'FOR' vote on all proposals, indicating a strategic push for increased financial flexibility.

Why It Matters

This DEF 14A filing is crucial for VTAK investors as the proposed 733% increase in authorized common stock from 60 million to 500 million shares could lead to significant dilution if new shares are issued. This move provides the company substantial flexibility for future capital raises, mergers, or acquisitions, which could impact the stock price and ownership percentages. For employees, potential capital infusion could stabilize operations or fund growth initiatives, while customers might see accelerated product development. In the competitive medical device market, this financial maneuver could enable VTAK to better compete by funding R&D or market expansion, but also signals a potential need for substantial external financing.

Risk Assessment

Risk Level: high — The proposal to increase authorized common stock from 60 million to 500 million shares represents a 733% potential increase, which carries a high risk of significant shareholder dilution. While the filing doesn't explicitly state an immediate issuance plan, such a large authorization often precedes substantial capital raises or strategic transactions that could depress per-share value for the 1,487,266 shares currently outstanding.

Analyst Insight

Investors should vote 'AGAINST' Proposal No. 1 to signal concern over potential dilution, unless the company provides a clear, value-accretive plan for the additional shares. Closely monitor VTAK's subsequent filings for any announcements regarding new share issuances or capital raises, as these will directly impact the stock's valuation.

Key Numbers

• 60 million — Current authorized common stock shares (Proposed to increase to 500 million shares)
• 500 million — Proposed authorized common stock shares (Represents a 733% increase from current authorization)
• 1,487,266 — Shares of Common Stock issued and outstanding (As of the September 10, 2025 record date)
• 74 — Holders of record (As of the September 10, 2025 record date)
• October 10, 2025 — Date of Special Meeting (Stockholders will vote on proposals)
• September 10, 2025 — Record Date (Determines eligibility to vote at the Special Meeting)
• 495,756 — Shares required for quorum (One-third of the 1,487,266 outstanding shares)

Key Players & Entities

• Catheter Precision, Inc. (company) — Registrant and medical device company
• David A. Jenkins (person) — Executive Chairman of the Board and Chief Executive Officer
• Philip Anderson (person) — Chief Financial Officer
• WithumSmith+Brown, PC (company) — Independent registered public accounting firm
• Equiniti Trust Company, LLC (company) — Transfer agent for Catheter Precision, Inc.
• Alliance Advisors, LLC (company) — Tabulator of votes and inspector of elections
• Securities and Exchange Commission (regulator) — Regulatory body for filing
• Delaware (regulator) — State of incorporation and governing law

FAQ

Risk Factors

• Significant Increase in Authorized Shares [high — financial]: The company is proposing to increase its authorized common stock from 60 million to 500 million shares, a 733% increase. This substantial expansion is intended to provide greater financial flexibility for future capital raises or strategic transactions, but it carries a significant risk of diluting existing shareholder value if not managed effectively.
• Reliance on Independent Auditors [medium — operational]: The company is seeking to ratify the appointment of WithumSmith+Brown, PC as its independent registered public accounting firm for the fiscal year ending December 31, 2026. While this is a standard procedure, any issues or disagreements with the auditors could impact financial reporting and investor confidence.

Industry Context

Catheter Precision, Inc. operates in the medical device sector, specifically focusing on catheter-based technologies. This industry is characterized by rapid innovation, stringent regulatory oversight (e.g., FDA approvals), and significant competition from both established players and emerging companies. Companies in this space often require substantial capital for research and development, clinical trials, and market expansion.

Regulatory Implications

The primary regulatory consideration for this filing is the disclosure requirements under SEC rules for proxy statements. The proposed increase in authorized shares, while a corporate governance matter, could have future implications if it facilitates significant capital raises or acquisitions that may require further regulatory review or filings.

What Investors Should Do

1. Review the proposed amendment to increase authorized shares.
2. Vote 'FOR' Proposal No. 1 (Certificate Amendment Proposal).
3. Vote 'FOR' Proposal No. 2 (Auditor Ratification Proposal).
4. Vote 'FOR' Proposal No. 3 (Adjournment Proposal).
5. Register to attend the Special Meeting by October 9, 2025.

Key Dates

• 2025-09-10: Record Date — Determines which stockholders are entitled to vote at the Special Meeting.
• 2025-09-15: Mailing of Proxy Materials — Informs stockholders about the upcoming Special Meeting and proposals, enabling them to review and vote.
• 2025-10-09: Registration Deadline for Special Meeting — Last day for stockholders to register to attend and vote at the Special Meeting via webcast.
• 2025-10-10: Special Meeting of Stockholders — The date on which stockholders will vote on key proposals, including the increase in authorized shares.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information to shareholders about matters to be voted on at a special meeting. (This document is the proxy statement for Catheter Precision, Inc.'s special meeting, outlining the proposals and providing information for stockholders to make informed voting decisions.)

Certificate of Incorporation

The foundational legal document that establishes a corporation and outlines its basic structure, purpose, and powers. (An amendment to the Certificate of Incorporation is required to increase the number of authorized shares of common stock.)

Authorized Shares

The maximum number of shares of stock that a corporation is legally permitted to issue, as specified in its Certificate of Incorporation. (The company is seeking to significantly increase its authorized shares from 60 million to 500 million.)

Independent Registered Public Accounting Firm

An external audit firm hired by a company to conduct an independent examination of its financial statements. (The company is seeking stockholder ratification for the appointment of WithumSmith+Brown, PC as its auditor for fiscal year 2026.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive notice of and vote at a shareholder meeting. (September 10, 2025, is the record date for determining voting eligibility for the Special Meeting.)

Street Name

Refers to shares of stock held in an account by a broker, bank, or other nominee on behalf of the beneficial owner. (Explains how beneficial owners, whose shares are held in street name, can vote their shares.)

Year-Over-Year Comparison

This filing is a proxy statement for a special meeting and does not contain comparative financial data from a previous annual report. The key focus is on the proposed increase in authorized shares from 60 million to 500 million, a significant change aimed at future financial flexibility. No information on revenue, net income, or margins is provided in this specific document, as it pertains to a special meeting agenda rather than a full financial reporting period.

Key Financial Figures

• $15,000 — ments, which are not expected to exceed $15,000 in total. Other than with respect to Al

Filing Documents

• vtak20250909_def14a.htm (DEF 14A) — 294KB
• a01.jpg (GRAPHIC) — 222KB
• a02.jpg (GRAPHIC) — 118KB
• jenkinssig.jpg (GRAPHIC) — 5KB
• logolarge.jpg (GRAPHIC) — 44KB
• 0001437749-25-029014.txt ( ) — 831KB

From the Filing

DEF 14A 1 vtak20250909_def14a.htm FORM DEF 14A vtak20250909_def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a 6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a12 Catheter Precision, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 011. 1670 Highway 160 West Suite 205, Fort Mill, SC 29708 (973)-691-2000 To our Stockholders: We are pleased to invite you to attend the special meeting of stockholders (the "Special Meeting") of Catheter Precision, Inc. (the "Company"), to be held on October 10, 2025 at 11:00 a.m. Eastern Standard Time, or at any adjournment or postponement thereof. At the Special Meeting, you will be asked to approve a number of proposals, as described below. You are invited to attend and vote your shares at the Special Meeting live via internet webcast so long as you register to attend the Special Meeting at web.viewproxy.com/VTAKSM/2025 by 11:59 p.m. Eastern Standard Time on October 9, 2025 (the "Registration Deadline"). Questions will need to be submitted prior to the Special Meeting. To submit questions, please visit web.viewproxy.com/VTAKSM/2025 . You will not be able to attend the Special Meeting in person . At this Special Meeting, our stockholders will be asked to: approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from sixty (60) million shares to five hundred (500) million shares (the "Certificate Amendment Proposal" or "Proposal No. 1"); ratify the appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ended December 31, 2026, (the "Auditor Ratification Proposal" or "Proposal No. 2"); and approve the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposals Nos. 1 and/or 2 (the "Adjournment Proposal" or "Proposal No. 3"). Details regarding how to attend the Special Meeting and the business to be conducted at the Special Meeting are more fully described in the accompanying notice of Special Meeting of stockholders and proxy statement. Your vote is important. Regardless of whether you plan to attend the Special Meeting, it is important that your shares be represented and voted at the Special Meeting, and we hope you will vote as soon as possible. You may vote by proxy via the Internet, by telephone, or by mail, according to the instructions on the enclosed proxy card or voting instruction card. Voting over the Internet or by telephone, by written proxy or voting instruction card will ensure your representation at the Special Meeting regardless of whether you attend the Special Meeting. Thank you for your ongoing support of, and continued interest in, Catheter Precision, Inc. Sincerely, David A. Jenkins Executive Chairman of the Board Fort Mill, South Carolina September 15, 2025 This proxy statement and accompanying proxy card are being mailed on or about September 15, 2025 to all stockholders entitled to vote at the Special Meeting. Important Notice Regarding the Availability of Proxy Materials for the Special Meeting to Be Held on October 10, 2025 . Our Proxy Statement, Proxy Card, and the Notice of the Meeting, are available at web.viewproxy.com/VTAKSM/2025 and are available from the SEC on its website at www.sec.gov. CATHETER PRECISION, INC. 1670 Highway 160 West Suite 205, Fort Mill, SC 29708 (973)-691-2000 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS Time and Date 11:00 a.m. Eastern Standard Time, on October 10, 2025, or any adjournment or postponement thereof. Webcast Address web.viewproxy.com/VTAKSM/2025 Items of Business to approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from sixty (60) million shares to five hundred (500) million shares (the "Certificate Amendment Proposal" or "Proposal No. 1"); to ratify the appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ended December 31, 2026, (the "Auditor Ratification Proposal" or "Proposal No. 2"); and to approve the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposals Nos. 1 and/or 2 (the "Adjournment Proposal" or "Propos

View Full Filing

View this DEF 14A filing on SEC EDGAR